

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)


1. Your Name: Segaran Pillai		
2. Your Title: Director, Office of Laboratory Science and Safety		
3. The Entity(ies) You are Representing: Food and Drug Administration, Department of Health and Human Services		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes X	No
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed. None		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: _____



Date: 4/18/2016

Segaran P. Pillai, Ph. D., SM (AAM), SM (ASCP)



PROFILE

Committed, resourceful, innovative, creative, level-headed, attentive to details, profound problem solving skills, proactive, ambitious, willing to accept new challenges, success-oriented, self-motivated, workplace stress resistant, adaptable team player, analytical mind, technically proficient, passionate about science and protecting public health and the safety of the Nation, advancing public health by developing innovative diagnostics and medical countermeasures that are affordable and effective, enhancing the Nation's capability and preparedness to counter terrorism, regulatory procedures and implementation of policies, succeeds in accomplishing variety of tasks, derives deep satisfaction from applying expertise, high ethical values, and believes in a teamwork environment.

EDUCATION

Ph.D. Aug. 1990 – Nov. 1995: Doctor of Philosophy: Biochemistry/Molecular Genetics
University of Kansas

M.S.(Hon) May 89 – Jul. 1990: Master of Science with Graduate Dean's Scholastic Honors
Major: Biology (Medical Physiology)
Pittsburg State University

B.S. (Hon) Jan. 87 – May 1989: Bachelor of Science with Departmental Academic Honors
Major: Biology (Microbiology), Minor: Chemistry
Pittsburg State University

PROFESSIONAL EXPERIENCE

3/07 – present **Chief Medical and Science Advisor, U.S. Department of Homeland Security, Science and Technology Directorate, Chemical and Biological Defense Division, Washington, D.C.**
(ST Level 2 with Certified Performance Appraisal)

DUTIES

- Oversee strategic planning and interagency interactions to support Threat Awareness, Prevention and Protection, Surveillance and Detection, and Response and Recovery related activities and initiatives.
- Provide clearance to all outgoing documents and testimonies; participate in executive level White House initiatives/meetings such as the National Biosurveillance initiative in collaboration with senior leaders from HHS ASPR, DoD, FBI, FDA, CDC, USDA, EPA, and

others; brief Congress and congressional staffers; draft, brief and prepare the Under Secretary for hearings; and deliver testimonies at Congressional hearings.

- Provide project status updates to senior management (Under Secretary for Science and Technology Directorate and HSARPA Director); direction to Program Managers and Branch Chiefs to ensure that projects have a clearly defined Project Management Agreement or Project Management Plan; management support to draft Performance Standards for Program Managers/Branch Chiefs and participate in the Performance Appraisal at the end of the cycle; and leadership and technical guidance to 20+ Science and Engineering Technology Associates (SETA's) in the division.
- Identify opportunities for capability development that significantly advance homeland security objectives and potential collaborations within other DHS components (CBP, TSA, USSS, OHA etc.) and the interagency (FDA, CDC, HHS ASPR, FBI, USDA, EPA, etc.) that provide innovative solutions to DHS end users.
- Develop a strategic plan detailing how the division will provide mission capabilities using innovative projects within the portfolio and a corresponding programmatic roadmap that connects the investment portfolio to capabilities and component missions to guide budget development.
- Serve as DHS lead for several interagency executive level committees and working groups such as the CDC Intergovernmental Select Agents and Toxins Technical Advisory Committee (CDC-ISATTAC); The Agriculture Interagency Select Agents and Toxins Technical Advisory Committee; the Pandemic Risk Management Group; the Emergency Use Authorization Working Group; the Biological MCM Working Group; the Public Health Emergency Medical Countermeasure Enterprise; HHS ASPR's Anthrax IPT, VHF IPT, Broad Spectrum Antimicrobial IPT, Enterprise Executive Council, and Enterprise Senior Council; the Emerging Infectious Disease Working group co-lead by CDC; and the Federal Expert Security Advisory Panel

ACCOMPLISHMENTS

- Provided technical subject matter expertise and worked with other SMEs from CDC, FDA, NIH/NIAID, USDA, DoD at the executive level to successfully complete the biannual select agent tiering and biannual overlap select agent tiering to include foreign animal and high consequence agricultural pathogens to support USDA APHIS to fulfill the Federal Expert Security Advisory Panels requirements in 2014. Represented DHS at multiple executive level meetings with the Executive Office of the President, Office of Science and Technology Policy to develop Executive Order 13546 - Optimizing the Security of Biological Select Agents and Toxins in the United States, signed by the President in 2010, to decrease the threat of biological weapons while reducing hurdles for research scientists.
- Testified on behalf of DHS before the U.S. House Committee on Homeland Security, Subcommittee on Emergency Preparedness, Response, and Communications, "Taking Measure of Countermeasures (Part 1)" in April 2011.
- Successfully led efforts to develop multiple high level strategy and policy documents including a National Biodefense Strategy to support DHS programs and activities; the Enhanced and Advanced Threat Agent Architectures; the DHS Implementation Plan for Countering Biological Threats in support of Presidential Policy Directive 2; and the Strategic Implementation Plan for Material Threat Assessments supporting HHS's medical countermeasure procurement decisions. Contributed to the development of the Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Implementation Plan and the National Health Security Strategy of the United States of America.

- Served as the DHS Executive Final Fee Determining/Management Official for oversight and performance of DHS National Bio Defense Analysis and Characterization Center/ National Bio Forensics Analysis Center at Fort Detrick, Maryland from 2007-2010 and effectively implemented a robust research program and process for select agent control and inventory for all DHS laboratories and facilities, including performers in coordination with DHS S&T Compliance Assurance Program Office.
- Successfully developed the Federal Standards for Evaluating Assay Performance and Equivalency to expedite consequence management efforts in responding to intentionally released pathogens detected by federal bio-monitoring programs and the Public Health Actionable Assays to provide CDC LRN laboratories with high confidence screening, detection, confirmation, and characterization assays in collaboration with multiple Federal agencies, State and Local Public Health departments, key professional associations and members of the academic community.

3/05 - 8/07 **Senior Medical and Science Advisor, Department of Homeland Security, Science and Technology Directorate from 3/05 - 3/07**
Chief Medical and Science Advisor, Department of Homeland Security, Science and Technology Directorate fro, 03/07 - 08/07

DUTIES

- Served as the Senior/Chief Medical and Science Advisor to DHS S&T in the Plan, Program and Requirements Office directly under the Assistant Secretary for Science and Technology Directorate from Florida Department of Health under an Intergovernmental Personnel Act (IPA). In this role, was responsible for briefing the Secretary of DHS in preparation for senior level Top-Off exercise and representing DHS at many executive level National Forums and meetings on behalf of the Under Secretary, Assistant Secretary and Office Directors of the Science and Technology Directorate.
- Effectively defined the vision, strategic plan and requirements for the Chemical and Biological Division and future generation of biomonitoring systems for integration into a national biomonitoring system. Successfully built interagency partnerships with CDC, DOD and EPA to accomplish this biomonitoring strategy by clearly defining agency roles and responsibilities.
- Represented the Directorate at the Executive level to support BioShield, BioWatch and BioSense related activities in a variety of interagency, technical and federal forums. Developed SOPs to include training, quality assurance, quality control, and a robust select agent inventory control program for the BioWatch program.
- Serve as senior liaison to the Public Health Community through their professional societies and at the local level to improve the understanding and acceptance of federal efforts for a safer and secure nation.

ACCOMPLISHMENTS

- Developed plans, programs, budgets and requirements for execution of DHS S&T's Chemical, Biological and Agricultural defense programs. (Approximate budget \$200M/year). Teamed with other division directors in DHS S&T to draft the necessary congressional justification documents to support DHS S&T's budget and activities.
- Teamed with federal, state, local, and private sectors to draft and implement a robust response strategy to a large release of biological attack and a wide area decontamination and restorations efforts.
- Successfully represented DHS priorities and activities in many executive level HHS Bio-

Shield and Homeland Security Council White House activities including briefing the White House Homeland Security Council and leading the DHS Material Threat Assessment studies for initiating the Material Threat Determination as required by the Project Bio-Shield Act 2004 for use of Bio-Shield Reserve Funds (\$5.6 Billion) to develop and procure appropriate medical countermeasures.

- Provided executive level oversight of the DHS Centers for Excellence activities to ensure the programs operate within the mission, activities were funded at the right level, progress and accomplishments were reviewed, and the programs complied with 42 CFR to ensure Bio Safety, Security and Surety.
- Led DHS participation in White House executive level meeting hosted by the Homeland Security Council and worked with other agencies to develop Executive Order 13486 - Strengthening Laboratory Biosecurity in the United States and to review the effectiveness of biosecurity policies regarding select agents and toxins. This Executive Order was signed by President Bush on January 9, 2009.

8/00 – 3/05 **Director of the Florida Department of Health, State Public Health Laboratory in Miami Florida**
Director for Clinical Services, Florida Department of Health, Miami-Dade County Health Department

DUTIES

- Managed, supervised and provided oversight of the Miami State Public Health Laboratory and 13 Miami Dade County Public Health Laboratories (approximately 100 employees) and established performance standards and conducted year-end performance appraisals for five direct reports from the State Lab and 13 direct reports from the Miami Dade County Health Department.
- Ensured lab compliance with CLIA rules and regulations and participated in Compliance Assurance and Proficiency Testing program.
- Confirmed lab completion of the necessary clinical, water and environmental sample testing and reporting of results in a timely manner.
- Implemented necessary protocols, training and procedures for compliance to 42 CFR to maintain and work with Biological Select Agents.

ACCOMPLISHMENTS

- Successfully implemented state-of-the-art technology for clinical and non-clinical specimen testing and evaluation to enhance the State of Florida's capability and robustness to support diagnostics, surveillance and detection including Ligase Chain Reaction, Strand Displacement Amplification, Transcription Mediated Amplification chemistries and Real-time PCR for the rapid detection of WNV, WEE, EEE, SLE, and Lac viruses for surveillance. Received the Robert D. May, M.D. Award in recognition of significant accomplishment in the advancement of Public Health at the Local and State Level in 2004.
- Successfully executed a balanced budget by working with leadership team and accountants enabling the lab to generate revenue for the first time (about \$8 million/year). Received the Davis Productivity Award three years in a row (2002, 2003 and 2004) for execution of a balanced budget and revenue generation.
- Led a team of scientists to design and establish a BSL-3 Bio-Terrorism Preparedness and Response Laboratory in Miami which became part of the CDC Laboratory Response Network. This lab passed the BSL-3 Certification without any issues and became one of the

first labs in the nation with real-time PCR capability that was capable of providing critical laboratory testing and confirmation during the 2001 Anthrax attack.

- Implemented critical standards for operation across the labs by employing robust Quality Control and Quality Assurance measures, Proficiency Testing, Training Programs, and timely reporting processes resulting in a reduction of CLIA violations and deficiencies from 102 to 2 within the first year of employment. The following three years, the labs passed CLIA inspection without any citations, violations or deficiencies and also passed the CAP proficiency testing with a 100%.
- Contributed to the first FDA cleared test for clinical identification of Bacillus anthracis for Blood Culture plates.
- Supervised a team of microbiologists to support the 2001 Anthrax attacks in South Florida while working closely with the Public Health, CDC, FBI and multiple federal, state and local law enforcement agencies as well as the first responder community. Served as a lead investigator and provided laboratory support for over 1,000 clinical samples and 13,000 environmental samples. Successfully addressed the threat as a result of well-established standard operating procedures for chain of custody, inventory control, and safety controls as well as proper technology, training, and tools necessary for working with select agents. As a result of the lab's response to the 2001 Anthrax attacks, the lab received recognition and awards from multiple agencies including acknowledgment by the CDC Director, Dr. Gerberding, as the model CDC LRN Select agent laboratory because of our timely response to the crises and the process implemented to support receiving, tracking, testing, shipping and reporting of results associated with select agents.

- 9/99 – 8/00 Research Assistant Professor, University of Kansas, Depts. of Molecular Biosciences and Medicinal Chemistry
- 6/98 – 8/99 Senior Research Associate, University of Kansas, Depts. of Molecular Biosciences and Medicinal Chemistry
- 6/96 – 5/98 Post-Doctoral Research Associate, University of Kansas, Dept. of Medicinal Chemistry
- 9/90 – 5/96 Graduate Research Assistant, University of Kansas, Dept. of Biochemistry

BOARD CERTIFICATIONS

- “Specialist Microbiologist in General Microbiology and in Public Health and Medical Laboratory Microbiology” American Academy of Microbiology. National Registry of Certified Microbiologist. (1997).
- “Specialist Microbiologist” American Society for Clinical Pathologists. (2005).

CLINICAL LICENSURE

- State of Florida, Department of Health, Division of Medical Quality Assurance,
 - Clinical Laboratory Director License DI36661 in the following areas:
 - Microbiology
 - Serology

- Clinical Chemistry
- Hematology
- Immunohematology
- Molecular Pathology
- Cytology
- Cytogenetics
- Molecular Genetics

COURSES AND TRAINING

Eckerd College – Leadership Development Institute

- Leadership Development Training 2009

Defense Acquisition University

- Contracting Officer's Representative (COR) CLC222 Section 890
- Market Research for Technical Personnel CLE028 Section 889
- Improved Statement of Work CLM031 Section 890
- Introduction to Earned Value Management CLV016 Section 889
- IPT Management and Leadership CLM014 Section 888
- Risk Management CLM017 Section 888
- Contracting Officer's Representative (COR) CLC222 Section 890

Department of Homeland Security

- Ethics and Procurement Integrity for the Acquisition Workforce FAC043 Section 888
- Information Systems Security Awareness
- Ethics Training (General Provision, Gifts between Employees, Conflicting Financial Interests, Impartiality in Performing Official Duties, Seeking Non-Federal Employment, Misuse of Position, Outside Activities)
- Federal Travel Regulations
- Senior Leader (SL) and Scientific Professional/Technical (ST) Performance Management System: Performance Plan Training
- Intelligence Community Information Assurance Awareness
- DHS Preparedness: Recurring List of EPI Core Items
- Emergency and Disaster Preparedness

Federal Acquisition Institute

- Contract Management: Strategies for Mission Success FAC033 Section 889
- Contracting Officer's Representative Level III Certification

Emergency Management Institute (FEMA)

- An Introduction to Hazardous Materials - IS-00005.a
- National Incident Management System (NIMS) an Introduction - IS-700
- Basic Incident Command System - IS-195
- Continuity of Operations (COOP) Awareness Course - IS-00546.a
- Preparedness for Federal Employees in the National Capital Region - IS-450NC
- Active Shooter: What You Can Do – IS-907
- Anthrax Awareness – IS-451

ACADEMIC AWARDS AND HONORS

- Kansas Health Foundation Scholar in Cancer Research, University of Kansas, 1993 - 1995.
- Kansas Health Foundation Post-Doctoral Scholar in Cancer Research, University of Kansas, 1996.
- Environmental Mutagen Society 2000 Young Investigator Award.
- International Conference on Anti-mutagenesis and Anti-carcinogenesis Mechanisms 2000 Young Investigator Award
- Davis Productivity Award, Certificate of Commendation, 2002, 2003, and 2004
- Prestigious Iceberg Award - Department of Justice, Federal Bureau of Investigation, for the invaluable support to the criminal investigation of the 2001 Anthrax attack. November 2001
- United State Postal Service Award, May 2003
- Federal Bureau of Investigation, Certificate of Recognition for the Anthrax investigation 2003
- Florida Department of Law Enforcement, Certificate of Appreciation, 2003
- Proclamation from Miami-Dade County Health Department for Public Health Services, 2003
- Florida Department of Health, Secretary of Health, Certificate of Commendation, 2003
- Pittsburg State University, Outstanding Alumni of Year Award, 2004
- ATSDR Award in recognition of the valuable laboratory contribution to the forensic examination associated with the 2001 Anthrax attack of the AMI Building, 2004
- Certificate of Appreciation by DHS Secretary Tom Ridge in recognition of outstanding contribution to the successful deployment of Bio-Watch monitoring System, 2004
- Robert D. May, M.D. Award in recognition of significant accomplishment in the advancement of Public Health at the local and State Level, 2004
- Miami Dade County Legislative Delegation Proclamation, 2005
- DHS Under Secretary for Science and Technology Special Act Award, 2008 in recognition for resolving the *F. tularensis* hits in Bio-Watch
- DHS Under Secretary's Award for Science and Technology for outstanding leadership and accomplishments 2008.
- DHS Under Secretary for Science and Technology Special Act Award, 2009 – recognition for leading the Bio-Net Preparedness Working Group and completion of the final report.
- DHS S&T Award 2009 – For leading the effort in developing the DHS Implementation Plan for National Strategy for Countering Biological Threats; Presidential Policy Directive 2.
- Executive Office of the President, Office of Science and Technology Policy, in recognition for the dedicated service and technical contribution towards the development of the executive order 13546 on optimizing the security of biological select agents and toxins in the U.S. 2010

PROFESSIONAL AFFILIATIONS

- Honorary Member of the Tri Beta Society
- Honorary Member of the Phi Kappa Phi for Academic Excellence
- Member of the American Society for Microbiology
- Member of the Environmental Mutagen Society
- Member of Sigma Xi, The Scientific Research Society
- Member of The New York Academy of Sciences

- Member of the American Association for the Advancement of Science
- Member of the Phi Beta Delta, Honor Society for International Scholars
- Member of the Florida Public Health Association
- Member of the Association for Public Health Laboratories
- Member of the Association for Food and Drug Officials

PUBLICATIONS

- Pillai, S. P.** (1990) "The Effect of Bitter Gourd Extract on Streptozotocin Induced Diabetic Mice". [M. S. Thesis—Pittsburg State University, Pittsburg, Kansas, USA]
- Pillai, S. P.** (1995) "Prevention of the Development of Multiple Antibiotic Resistance". [Ph. D. Dissertation— University of Kansas, Lawrence, Kansas, USA]
- Pillai, S. P.,** and D. M. Shankel (1997) "Polyamines and their Potential to be Antimutagenic". *Mutation Research* 377:217-224.
- Mitscher, L. A., M. Jung D. M. Shankel, J. H. Dou, L. Steele, and **S. P. Pillai** (1997) "Chemoprotection: A Review of the Potential Therapeutic Antioxidant Properties of Green Tea (*Camellia sinensis*) And Certain of its Constituents". *Medicinal Research Reviews*, Vol. 17, No. 4, 327-365.
- Pillai, S. P.,** and D. M. Shankel (1998) "Effects of Antimutagens on Development of Drug/Antibiotic Resistance in Microorganisms". (Fundamental and Molecular Mechanisms of Mutagenesis) *Mutation Research (Special Issue: 5th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis)*. Vol. 402 Nos. 1, 2, pp 139-150.
- Mitscher, L. A., **S. P. Pillai,** S. R. Menon, C. A. Pillai, and D. M. Shankel (1999) "Naturally Occurring Antimutagens and Cytoprotective Agents", "Biologically Active Natural Products: Agrochemicals and Pharmaceuticals" S. J. Cutler and H. G. Cutler, eds., CRC Press, Boca Raton, FL, 1999, 133.
- Menon, S. R., V. K. Patel, L. A. Mitscher, P. Shih, **S. P. Pillai,** and D. M. Shankel (1999) "Structure-Antimutagenic Activity Relationship Study of Plicatin B". *Journal of Natural Products* Vol. 62, No.1, 102-106.
- Mitscher, L. A., **S. P. Pillai,** E. Gentry, and D. M. Shankel. (1999) "Multiple Drug Resistance" *Medicinal Research Reviews*, Vol. 19, No. 6, 477-496.
- Pillai, S. P.,** L. A. Mitscher, S. R. Menin, C. A. Pillai and D. M. Shankel. (1999) "Antimutagenic/Antioxidant activity of green tea components and related compounds (Special Issue: 6th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis). *Journal of Environmental Pathology, Toxicology and Oncology*, Vol. 18, No. 3. 147-158.
- Pillai, S. P.,** S. Menon, L. A. Mitscher, C. A. Pillai, and D. M. Shankel (1999) " Umbelliferone analogs and Their Potential to Inhibit Benzo(a)pyrene- and Hydrogen Peroxide-Induced Mutations" *Journal of Natural Products* Vol. 62, No. 10, 1358-1362.
- Shankel, D. M., **S. P. Pillai,** H. Telikepalli, S. R. Menon, C. A. Pillai, and L. A. Mitscher (2000) "Role of Antimutagens/Anticarcinogens in Cancer Prevention", *BioFactors* 12, 113-121.

Mitscher, L. A., **S. P. Pillai**, D. M. Shankel (2000) "Some Transpacific Thoughts on the Regulatory Need for Standardization of Herbal Medical Products", *Journal of Food and Drug Analysis* Vol. 8, No. 4, 229-234.

Jernigan J. A., D. S. Stephens, D. A. Ashford, C. Omenaca, M. S. Topiel, M. Galbraith, M. Tapper, T. L. Fisk, S. Zaki, T. Popovic, R. F. Meyer, C. P. Quinn, S. A. Harper, S. K. Fridkin, J. J. Sejvar, C. W. Shepard, M. McConnell, J. Guarner, W. J. Shieh, J. M. Malecki, J. L. Gerberding, J. M. Hughes, B. A. Perkins, Anthrax Bioterrorism Investigation Team (J. Aguilar, M. Andre, K. Baggett, B. Bell, D. Bell, M. Bowen, G. Carlone, M. Cetron, S. Chamany, B. De, C. Elie, M. Fischer, A. Hoffmaster, K. Glynn, R. Gorwitz, C. Greene, R. Hajjeh, T. Hilger, J. Kelly, R. Khabbaz, A. Khan, P. Kozarsky, M. Kuehnert, J. Lingappa, C. Marston, J. Nicholson, S. Ostroff, T. Parker, L. Petersen, R. Pinner, N. Rosenstein, A. Schuchat, V. Semenova, S. Steiner, F. Tenover, B. Tierney, T. Uyeki, S. Vong, D. Warnock, C. Spak, D. Jernigan, C. Friedman, M. Ripple, D. Patel, **S. Pillai**, S. Wiersma, R. Labinson, L. Kamal, E. Bresnitz, M. Layton, G. DiFerdinando, S. Kumar, P. Lurie, K. Nalluswami, L. Hathcock, L. Siegel, S. Adams, I. Walks, J. Davies-Coles, M. Richardson, K. Berry, E. Peterson, R. Stroube, H. Hochman, M. Pomeranz, A. Friedman-Kien, D. Frank, S. Bersoff-Matcha, J. Rosenthal, N. Fatteh, A. Gurtman, R. Brechner, C. Chiriboga, J. Eisold, G. Martin, K. Cahill, R. Fried, M. Grossman, and W. Borkowsky). (2001) "Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United State" *Emerging Infectious Diseases* Vol. 7, No.6, 933-943

Traeger M. S., S. T. Wiersma, N. E. Rosenstein, J. M. Malecki, C. W. Shepard, P. L. Raghunathan, **S. P. Pillai**, T. Popovic, C. P. Quinn, R. F. Meyer, S. R. Zaki, S. Kumar, S. M. Bruce, J. J. Sejvar, P. M. Dull, B. C. Tierney, J. D. Jones, B. A. Perkins, and the Florida Investigation Team" (2002) "First Case of Bioterrorism-Related Inhalational Anthrax in the United States, Palm Beach County, Florida, 2001" *Emerging Infection Diseases* Vol. 8, No. 10, 1029-1034.

Polyak, C. S., J. T. Macy, M. I. De La Cruz, J. E. Lai, J. F. McAuliffe, T. Popovic, **S. P. Pillai**, E. D. Mintz and the Emergency Operation Center International Team. (2002) "Bioterrorism-Related Anthrax: International Response by the Centers for Disease Control and Prevention" *Emerging Infectious Diseases* Vol. 8, No 10, 1056-1059.

Pillai, S. P., C. A. Pillai, D. M. Shankel, and L. A. Mitscher (2000) "The ability of certain antimutagenic agents to prevent development of antibiotic resistance" *Mutation Research* 496, 61-73.

Barry, J. T., J. A. Bellamy, E.A. Bresnitz, J. Casani, M. DeZearn, T. A. Dixon, M. K. Elliott, C. R. Friedman, W. Greim, K. N. Harmon, S. Noem, D. A. Olshack, B. A. Perkins, P. H. Perkins, **S. P. Pillai**, E. Richardson, M. L. Sanders, R. M. Scripp, D. L. Steele, R. Stryker, C. S. Watz, T. H. York, W. A. Zinnikas (2002) "Criminal and Epidemiological Investigation Handbook"

Siddaramappa, S., J. F. Challacombe, J. M. Peterson, **S. P. Pillai**, G. Hogg, and C.R. Kuske (2011) "Common Ancestry and Novel Genetic Traits of *Francisella novicida*-Like Isolates from North America and Australia as Revealed by Comparative Genomic Analyses" *Applied and Environmental Microbiology* Vol 77(15), 5110-5122.

Peterson, J.M., J. Carlson, B. Yockey, **S. P. Pillai**, C. Kuske, G. Garbalena, S. Pottumarthy, and L. Chalcraft (2009) "Direct isolation of *Francisella* spp. from environmental samples" *Letters in Applied Microbiology* Vol 48, 663-667.

- Menon, S., H. Vaidya, **S. P. Pillai**, R. Vidya, and L. A. Mitscher (2003) "A Parallel Synthesis Demonstration Library of Tri-Substituted Indazoles Containing New Antimutagenic/Antioxidant Hits Related to Benzydamine" *Combinatorial Chemistry & High Throughput Screening* Vol 6 Issue 5, 471-480.
- Pillai, S. P.**, C. Pillai, L. A. Mitscher, and R. Cooper (2007) "Use of quantitative flow cytometry to measure ex vivo immunostimulant activity of Echinacea: the case for polysaccharides" *Journal of Alternative and Complementary Medicine* Vol 13(6), 625-634.
- Fecik, R.A., P. Devasthale, **S. P. Pillai**, A. Keschavarz-Shokri, L. Shen, L.A. Mitscher (2005) "Chiral DNA gyrase inhibitors. 3. Probing the chiral preference of the active site of DNA gyrase. Synthesis of 10-fluoro-6-methyl-6,7-dihydro-9-piperazinyl-2H-benzo[a]quinolizin-20-one-3-carboxylic acid analogues" *Journal of Medicinal Chemistry* Vol 48(4), 1229-1236.
- Weigel, L. M., D. Sue, P.A. Michel, B. Kitchel, and **S. P. Pillai** (2010) "A Rapid Antimicrobial Susceptibility Test for *Bacillus anthracis*" *Antimicrobial Agents and Chemotherapy* Vol 54(7), 2793-2800.
- Elmir, S. M., M. E. Wright, A. Abdelzاهر, H. M. Solo-Gabriele, L. E. Fleming, G. Miller, M. Rybolowik, M. P. Shih, **S. P. Pillai**, J. A. Cooper, and E. A. Quaye (2007) "Quantitative evaluation of bacteria released by bathers in a marine water" *Water Research* Vol 41(1), 3-10.
- Ferguson, D. P., M. E. Pitesky, H. J. Tobias, P. T. Steele, G. A. Czerwieniec, S. C. Russell, C. B. Lebrilla, J. M. Horn, A. Srivastava, **S. P. Pillai**, M. P. Shih, and H. L. Hall (2004) "Reagentless Detection and Classification of Individual Bioaerosol Particles in Seconds" *Analytical Chemistry* Vol. 76, No. 2, 373-378.
- Siddaramappa, S., J. F. Challacombe, J. M. Petersen, **S. P. Pillai**, C. R. Kuske. "Genetic diversity within the genus *Francisella* as revealed by comparative analyses of the genomes of two North American isolate from environmental sources" *BMC Genomics* 2012, 13:422, 1-17.
- Ramage J., **Pillai S.**: The Public Health Response to Potential Bioterrorism by Toxin Attack. In: Gopalakrishnakone P. (Ed.) *Toxinology. Biological Toxins and Bioterrorism*: SpringerReference (www.springerreference.com). Springer-Verlag Berlin Heidelberg, 2013. 2014-04-22 11:48:08 UTC
- Hodge DR, Prentice KW, Ramage JG, Prezioso S, Gauthier C, Swanson T, Hastings R, Basavanna U, Datta S, Sharma SK, Garber EA, Staab A, Pettit D, Drumgoole R, Swaney E, Estacio PL, Elder IA, Kovacs G, Morse BS, Kellogg RB, Stanker L, Morse SA, **Pillai SP**. (2013) "Comprehensive Laboratory Evaluation of a Highly Specific Lateral Flow Assay for the Presumptive Identification of Ricin in Suspicious White Powders and Environmental Samples" *Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science*. 11(4): 237-250
- Ramage JG, Prentice KW, Morse SA, Carter AJ, Datta S, Drumgoole R, Gargis SR, Griffin-Thomas L, Hastings R, Masri HP, Reed MS, Sharma SK, Singh AK, Swaney E, Swanson T, Gauthier C, Toney D, Pohl J, Shakamuri P, Stuchlik O, Elder IA, Estacio PL, Garber EA, Hojvat S, Kellogg RB, Kovacs G, Stanker L, Weigel L, Hodge DR, **Pillai SP** (2014) "Comprehensive Laboratory Evaluation of a Specific Lateral Flow Assay for the Presumptive Identification of Abrin in

Suspicious White Powders and Environmental Samples” Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science. 12 (1): 49-62.

Siddaramappa, S, J. F. Challacombe, J. M. Petersen, **S. P. Pillai**, and C. R. Kuske. (2014) “Comparative Analyses of a Putative Francisella Conjugative Element” Genome 57: 1-8.

Shih, P., **S. P. Pillai**, S. Kuo, and D. M. Shankel (1993) “Examination of Monosodium Glutamate Genotoxic and Mutagenic Potentials” Environmental and Molecular Mutagenesis Vol. 21 Supplement 22. P.65 [Abstract]

Pillai, S. P., P. Shih, and D. M. Shankel (1994) “Prevention of Drug Resistant by Polyamines”. Environmental and Molecular Mutagenesis Vol.23 Supplement 23. P53 [Abstract]

Pillai, S. P., P. Shih, C. A. Grimm, and D. M. Shankel (1995) “Evaluation of Drug Resistance Bacteria”. Environmental and Molecular Mutagenesis Vol 25 Supplement 25. P. 42 [Abstract]

Pillai, S. P., C. A. Grimm and D. M. Shankel (1996) “Prevention of Drug Resistant by Polyamines”. Environmental and Molecular Mutagenesis Vol 27 Supplement 27 p. 54 [Abstract]

Shankel, D. M., **S. P. Pillai** and L. A. Mitscher (1996) “Effects of Antimutagens on Development of Drug/Antibiotic Resistance in Microorganisms”. 5th International Conference of Mechanisms of Antimutagenesis and Anticarcinogenesis (5th ICMAA), Okayama, Japan [Abstract]

Pillai, S. P., L. A. Mitscher, S. R. Menon, C. A. Grimm, and D. M. Shankel (1998) “Antioxidants and the Prevention of Cellular/Genetic Damage” Environmental and Molecular Mutagenesis Vol 31 Supplement 29. p. 57 [Abstract]

Pillai, S. P., S. R. Menon, L. A. Mitscher, and D. M. Shankel (1998) “Antimutagenic/ Antioxidant activity of green tea components and related compounds”. 6th International Conference on Mechanisms of Antimutagenesis and Anticarcinogenesis), Arcachon, France [Abstract]

Pillai, S. P., S. R. Menon, H. Telikepalli, M. Gassen, C. A. Grimm, L. A. Mitscher, and D. M. Shankel (1999) “Glabrene analogs and their antioxidative properties” Environmental and Molecular Mutagenesis Vol 33 Supplement 30. P.50 [Abstract]

Grimm, C. A., **S. P. Pillai**, S. R. Menon, L. A. Mitscher, and D. M. Shankel (1999) “Indazoles and their antioxidative properties for the prevention of cellular/genetic damage” Environmental and Molecular Mutagenesis Vol 33 Supplement 30. P.27 [Abstract]

Pillai, S. P., L. A. Mitscher, C. A. Pillai, and D. M. Shankel (2000) “Antimutagens and their potential in the prevention of antibiotic resistance development” Environmental and Molecular Mutagenesis Vol 35 Supplement 31. p. 48 [Abstract]

PATENTS

Mitscher, L. A., **S. P. Pillai**, and R. Cooper. “Immunostimulant compositions and associated methods.” U.S. Patent 20020028258, filed May 9, 2001, and issued March 7, 2002.

Jampani, H.B., L. A. Mitscher, J. L. Newman, and **S. P. Pillai**. "Novel antimicrobial resistance blocking compositions" This invention is concerned with antimicrobial compositions that control or prevent resistance to antimicrobial effectiveness, more particularly to combinations of topical antimicrobial agents with antimutagenic or antioxidant agents that block intrinsic or acquired bacterial resistance. Patent WO 2003028762A1. Filed Sept. 28, 2001 and published Apr. 10, 2003.

Jampani, H. B., L. A. Mitscher, **S. P. Pillai**, and P. J. Trotter. "An antimicrobial composition comprising silver and at least one compound which is an inhibitor of microbial silver resistance. Inhibitor compounds include fusaric acid, tocopherol, resveratrol, and myristic acid. Also provided are wound dressings comprising the inventive compositions. Other exemplified inhibitors include green tea, curcumin and ellagic acid." United Kingdom Patent GB2402880, filed June 20, 2003, and issued December 22, 2004.

Jampani, H. B., L. A. Mitscher, J. L. Newman, and **S. P. Pillai**. "This invention is concerned with antimicrobial compositions that control or prevent resistance to antimicrobial effectiveness, more particularly to combinations of topical antimicrobial agents with antimutagenic or antioxidant agents that block intrinsic or acquired bacterial resistance." PCT Patent 2003/028762, filed September 28, 2001, and issued April 10, 2003.

REFERENCES

Stephen Morse, Ph.D.

Associate Director, Environmental Biology
National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention
Tel: 404-639-3559
Email: SAM1@cdc.gov

Dan Sosin, M.D.

Deputy Director and Chief Medical Officer
Office of Public Health Preparedness and Response, Centers for Disease Control and Prevention
Tel: 404-639-7855
Email: dms8@cdc.gov

Luciana Borio, M.D.

Assistant Commissioner for Counterterrorism Policy
Office of the Commissioner, Food and Drug Administration
Tel. (301)796-4637
Email: Luciana.Borio@fda.hhs.gov

Alan Liss, Ph.D.

Director, MCMi PHSAT, Office of Counterterrorism and Emerging Threats
Office of the Commissioner, Food and Drug Administration
Tel: 301-520-8982
Email: Alan.Liss@fda.hss.gov

Elizabeth George, Ph.D.

Director, Cooperative Threat Reduction Directorate
Defense Threat Reduction Agency, Department of Defense
Tel: 703-767-7785
Email: Elizabeth.George@dtra.mil